Status:
COMPLETED
Effect of Science Research Wellness Ndo1 on Glycaemia in Adults With Pre-diabetes
Lead Sponsor:
Wellizen Australia
Conditions:
Prediabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of this study is to test the effect of 12 weeks of supplementation SRW Ndo1 on metabolic health and general health in adults with prediabetes. The primary question it aims to answer are:...
Eligibility Criteria
Inclusion
- Age 18 years and over.
- Prediabetes, defined as fasting plasma glucose of 6.1-6.9 mmol/L and/or HbA1c of 5.7-6.4% and/or 2 h plasma glucose of 7.8-11.0 mmol/L after ingestion of 75 g of oral glucose load. Blood tests conducted within 3 months before randomisation will be accepted.
- Able to read and write English.
- Has access to internet.
- Provided informed consent to participate in the study.
Exclusion
- Has a medical condition known to affect the glycaemia.
- Regular intake of a health supplement with effects on glycaemia.
- Currently participating in another trial/study of a supplement or drug.
- Has any known food or allergy or intolerances to the ingredients of the intervention.
- Pregnant, trying to conceive or breastfeeding.
- Has any current substance abuse (including tobacco, alcohol and recreational drugs) or currently in substance withdrawal.
- Moderate to severe medical conditions (defined as a significant impact on social areas of functioning).
- Any medical conditions that was not stable over the last 3 months.
- Taking any prescription medication known to affect glycaemia or had a change in their medication within the last 3 months.
- Currently taking celiprolol, metformin, or any angiotensin-converting enzyme inhibitor medications.
- Major medical or surgical event requiring hospitalization within the last 3 months.
- Any other medical reason that may make participation in this study pose a risk to the participant, including potential herb-drug interactions, at the discretion of the study medical supervisor.
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 8 2025
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT06897462
Start Date
April 1 2025
End Date
July 8 2025
Last Update
July 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baohua
Guangzhou, Guandong, China